StockNews.com Upgrades uniQure (NASDAQ:QURE) to “Sell”

StockNews.com upgraded shares of uniQure (NASDAQ:QURE) to a sell rating in a research note issued to investors on Wednesday.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group upped their price target on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. HC Wainwright upped their price target on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Leerink Partners increased their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Finally, Guggenheim reissued a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.00.

uniQure Stock Down 9.7 %

Shares of NASDAQ:QURE opened at $14.63 on Wednesday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a fifty day moving average of $14.70 and a two-hundred day moving average of $9.19. The stock has a market cap of $713.07 million, a P/E ratio of -2.95 and a beta of 0.39. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. On average, research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in QURE. Marshall Wace LLP purchased a new position in shares of uniQure in the 2nd quarter valued at about $175,000. Algert Global LLC purchased a new position in shares of uniQure in the 2nd quarter valued at about $176,000. Cubist Systematic Strategies LLC increased its holdings in shares of uniQure by 130.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 14,454 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of uniQure by 49.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 89,400 shares during the last quarter. Finally, Ballentine Partners LLC purchased a new position in shares of uniQure in the 3rd quarter valued at about $116,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.